Daiichi Sankyo Company, Ltd
Daiichi Sankyo Company, Ltd (Daiichi Sankyo) is a Japan-based holding company engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company's business operations are classified into two segments: Pharmaceuticals and Others. The company's Pharmaceuticals segment, which comprises prescription drug business and the healthcare (OTC) business; manufactures and markets prescription drugs, OTC drugs, and quasidrugs. The Others segment is involved in the real estate leasing, the insurance agency business, as well as the provision of human affairs and accounting services. With about 2,300 overseas medical representatives, the company caters its products and services in 33 locations, including: Japan, North America, Europe, India, among others. The company is headquartered in Tokyo, Japan. In January 2009, the company established a new subsidiary in Puerto Rico. In February 2009, the company acquired New Delhi based Solrex Pharmaceuticals Company and the Netherlands based Ranbaxy (Netherlands) B.V. In February 2009, the company and Eli Lilly and Company received approval from the European Commission for Effient, for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI). In April 2009, the company and Eli Lilly and Company launched Efient in the UK. In July 2009, the company and Eli Lilly and Company was approved by the U.S. Food and Drug Administration (FDA) to market Effient for the reduction of thrombotic cardiovascular events in patients with acute coronary syndromes who are managed with PCI. In September 2009, the company announced that a subsidiary of Ranbaxy in Romania, Terapia S.A. (Terapia Ranbaxy), will market the ostcoporosis medication, Evista in Romania. In November 2009, the company entered into a licensing agreement with BioInvent, to discover and develop therapeutic antibodies.The company reported revenues of (Yen) JPY 842,147.00 million during the fiscal year ended March 2009, a decrease of 4.31% from 2008. The operating loss of the company was JPY 295,528.00 million during the fiscal year 2009, as against an operating income of JPY 139,678.00 million during 2008. The net loss of the company was JPY 215,495.00 million during the fiscal year 2009, as against a net profit of JPY 97,669.00 million during 2008.